NCT00006441 - Effectiveness of Adding Interleukin-2 to Anti-HIV Drugs in Patients Recently Infected With HIV | Biotech Hunter

Enrollment

398

Participants

Timeline

Start Date

February 28, 2003

Primary Completion Date

October 31, 2008

Study Completion Date

October 31, 2008

Conditions

HIV Infections

Interventions

DRUG

Lamivudine/Zidovudine

300/150 mg respectively twice daily for 104 weeks. Patients who develop intolerence to AZT may use Stavudine (d4T) at a dose of 40 mg daily.

DRUG

Nelfinavir mesylate

1250 mg twice daily for 104 weeks.

DRUG

Aldesleukin

7.5 million units twice daily. Treatment will last until conclusion of study.

Trial Locations (2)

University of Alabama- Birmingham, Birmingham

Rick Hecht, San Francisco